Praliciguat

Overview

Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase ( sGC ) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytokines and inhibit apoptosis . Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease , such as hypertension, diabetes and heart failure.

Application

Products | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Hypertension | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Guanylate Cyclase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-109039
• CAS No.: 1628730-49-3
• Molecular Formula: C21H14F8N6O2
• Molecular Weight: 534.36
• Purity: 99.35%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (3.89 mM); Clear solution
• Availability: In-stock

Source

Original product source